Related Experiment Videos
[Prognostic value of epidermal growth factor receptor]
Frédérique Penault-Llorca1, Xavier Durando, Jacques-Olivier Bay
1Département de pathologie, Centre Jean-Perrin, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand. fpenault@cjp.fr
Bulletin Du Cancer
|February 7, 2004
Summary
Epidermal growth factor receptor (EGFR) activation drives cancer growth and is a poor prognostic factor in many tumors. Further research is needed to confirm its prognostic value in certain cancers and explore its therapeutic potential.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor receptor (EGFR) activation is a key driver in oncogenesis.
- EGFR signaling promotes tumor growth, metastasis, and angiogenesis while inhibiting apoptosis.
- Abnormalities like increased ligand expression can lead to EGFR activation.
Purpose of the Study:
- To review the prognostic value of EGFR expression in various human cancers.
- To assess the potential of EGFR as a therapeutic target in oncology.
Main Methods:
- Retrospective analysis of existing studies on EGFR expression.
- Evaluation of EGFR's correlation with prognosis across different tumor types.
Main Results:
- EGFR expression is a significant prognostic factor in head and neck, cervical, esophageal, bladder, and ovarian cancers, often indicating a poor prognosis.
- Prognostic value of EGFR is not established in non-small cell lung cancer and requires further investigation in colorectal and breast cancers.
Conclusions:
- EGFR plays a critical role in cancer development and progression.
- EGFR's established prognostic value in several cancers suggests its potential as a future therapeutic target.